B. Riley Weighs in on OptimizeRx Co.’s Q2 2020 Earnings (NASDAQ:OPRX)

Share on StockTwits

OptimizeRx Co. (NASDAQ:OPRX) – Equities research analysts at B. Riley issued their Q2 2020 EPS estimates for OptimizeRx in a research note issued on Wednesday, November 6th. B. Riley analyst A. D’silva anticipates that the company will earn $0.06 per share for the quarter. B. Riley has a “Buy” rating and a $21.00 price objective on the stock. B. Riley also issued estimates for OptimizeRx’s Q3 2020 earnings at $0.05 EPS and Q4 2020 earnings at $0.09 EPS.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.15). OptimizeRx had a negative return on equity of 4.19% and a negative net margin of 5.32%. The firm had revenue of $5.00 million for the quarter, compared to analyst estimates of $7.21 million.

Several other analysts have also issued reports on OPRX. ValuEngine upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Zacks Investment Research lowered OptimizeRx from a “hold” rating to a “sell” rating in a report on Tuesday, November 5th.

Shares of OptimizeRx stock opened at $10.13 on Friday. OptimizeRx has a fifty-two week low of $8.92 and a fifty-two week high of $17.24. The firm has a market cap of $170.46 million, a price-to-earnings ratio of 202.60, a price-to-earnings-growth ratio of 1.50 and a beta of 0.42. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $13.49 and a 200-day simple moving average of $14.42.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN increased its position in OptimizeRx by 9.5% during the second quarter. Wells Fargo & Company MN now owns 13,562 shares of the company’s stock worth $219,000 after buying an additional 1,180 shares during the last quarter. 1492 Capital Management LLC grew its position in shares of OptimizeRx by 118.8% in the second quarter. 1492 Capital Management LLC now owns 265,185 shares of the company’s stock valued at $4,296,000 after purchasing an additional 144,006 shares during the last quarter. Calamos Advisors LLC grew its position in shares of OptimizeRx by 17.0% in the third quarter. Calamos Advisors LLC now owns 312,764 shares of the company’s stock valued at $4,529,000 after purchasing an additional 45,548 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of OptimizeRx in the second quarter valued at approximately $520,000. Finally, BlackRock Inc. grew its position in shares of OptimizeRx by 2,111.6% in the second quarter. BlackRock Inc. now owns 607,292 shares of the company’s stock valued at $9,839,000 after purchasing an additional 579,833 shares during the last quarter. 57.32% of the stock is currently owned by hedge funds and other institutional investors.

In other OptimizeRx news, CEO William J. Febbo purchased 5,000 shares of the stock in a transaction on Wednesday, November 6th. The shares were purchased at an average price of $10.38 per share, with a total value of $51,900.00. 8.40% of the stock is owned by insiders.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Featured Article: Convertible Shares

Earnings History and Estimates for OptimizeRx (NASDAQ:OPRX)

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.